Background. Renal and cardiac involvement is responsible for substantial morbidity and mortality in Fabry disease (FD). We analysed the incidence of FD-related renal, cardiac and neurologic end points in patients with FD on long-term enzyme replacement therapy (ERT). Methods. A retrospective analysis of prospectively collected data from two German FD centres was performed. The impact of renal and cardiac function at ERT-naïve baseline on end point development despite ERT was analysed. Results. Fifty-four patients (28 females) receiving ERT (mean 81 6 21 months) were investigated. Forty per cent of patients were diagnosed with clinical end points before ERT initiation and 50% of patients on ERT developed new clinical end points. In patients initially diagnosed with an end point before ERT initiation, the risk for an additional end point on ERT was increased fhazard ratio [HR] 3.83 [95% confidence interval (CI) 1.61-9.08]; P ¼ 0.0023g. A decreased glomerular filtration rate (eGFR) 75 mL/min/1.73 m 2 in ERT-naïve patients at baseline was associated with an increased risk for cardiovascular end points [HR 3.59 (95% CI 1.15-11.18); P ¼ 0.0273] as well as for combined renal, cardiac and neurologic end points on ERT ); P ¼ 0.0007]. In patients with normal kidney function, left ventricular hypertrophy at baseline predicted a decreased end point-free survival ); P ¼ 0.0018]. The risk to develop an end point was independent of sex. Conclusions. In addition to age, even moderately impaired renal function determines FD progression on ERT. In patients
A B S T R A C T
Background. Renal and cardiac involvement is responsible for substantial morbidity and mortality in Fabry disease (FD). We analysed the incidence of FD-related renal, cardiac and neurologic end points in patients with FD on long-term enzyme replacement therapy (ERT). Methods. A retrospective analysis of prospectively collected data from two German FD centres was performed. The impact of renal and cardiac function at ERT-naïve baseline on end point development despite ERT was analysed. Results. Fifty-four patients (28 females) receiving ERT (mean 81 6 21 months) were investigated. Forty per cent of patients were diagnosed with clinical end points before ERT initiation and 50% of patients on ERT developed new clinical end points. In patients initially diagnosed with an end point before ERT initiation, the risk for an additional end point on ERT was increased fhazard ratio [HR] 3.83 [95% confidence interval (CI) 1.61-9.08]; P ¼ 0.0023g. A decreased glomerular filtration rate (eGFR) 75 mL/min/1.73 m 2 in ERT-naïve patients at baseline was associated with an increased risk for cardiovascular end points [HR 3 .59 (95% CI 1.15-11.18); P ¼ 0.0273] as well as for combined renal, cardiac and neurologic end points on ERT [HR 4 .77 (95% CI 1.93-11.81); P ¼ 0.0007]. In patients with normal kidney function, left ventricular hypertrophy at baseline predicted a decreased end point-free survival [HR 6 .90 (95% CI 2.04-23.27); P ¼ 0.0018]. The risk to develop an end point was independent of sex. Conclusions. In addition to age, even moderately impaired renal function determines FD progression on ERT. In patients with FD, renal and cardiac protection is warranted to prevent patients from deleterious manifestations of the disease.
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I N T R O D U C T I O N
Fabry disease (FD; Online Mendelian Inheritance in Man 301500) is a rare, X chromosomal lysosomal storage disease caused by a deficiency of alpha galactosidase A enzyme activity caused by mutations in the alpha galactosidase A (GLA; 300644) gene. The enzymatic defect leads to the systemic accumulation of mainly globotriaosylceramide (Gb3) in different cells and tissues [1] . The first signs and symptoms, such as neuropathic and gastrointestinal pain, hypohidrosis and FD crisis, appear during early childhood [2, 3] . During disease progression, patients suffer from progressive renal failure, cardiomyopathy and recurrent strokes/transient ischaemic attacks (TIAs) [4] , resulting in an increased risk for early death if untreated. Treatment with enzyme replacement therapy (ERT) has repeatedly shown a reduction of subcellular Gb3 inclusions and a slowing of disease progression in affected patients [5] [6] [7] [8] . However, recent long-term analyses of agalsidase-alfa as well as agalsidase-beta treatment suggested substantially diverse frequencies of clinically relevant events and a decrease in organ function for FD patients on ERT [9] [10] [11] [12] [13] .
In the present study we analysed the incidence of clinically relevant renal, cardiac and neurologic FD-related end points in 54 patients with FD from two German FD centres. 
Furthermore, we focused on the predictive impact of renal function at baseline on disease progression on ERT.
M A T E R I A L S A N D M E T H O D S
Patients and study design A total of 54 adult patients with genetically confirmed FD who were enrolled at the FD centres of Muenster and Cologne between January 2002 and January 2016 were included in this study. Inclusion criteria were (i) a classical or late-onset clinical phenotype form of FD including FD-typical signs and symptoms (patients with genetic variants of unknown significance and polymorphisms were not included), (ii) an ERT-naïve status at baseline observation and (iii) continuous ERT treatment for at least 60 months. Compound switch (agalsidase-alfa, or agalsidase-beta) was not an exclusion criterion. An overview of detected GLA mutations and their clinical phenotypes is provided in Supplementary data, Table S1 . Investigations were performed after approval of the ethics committees of the participating centres (Medical Association of Westfalian-Lippe and the Ethical Committee of the Medical Faculty of the University of Muenster; Ethical Committee of the Medical Faculty of the University of Cologne; project 2011-347-f) and written informed consent of the patients for molecular analysis and publication was obtained.
The comprehensive routine assessment included renal, cardiac and neurologic parameters. The detailed clinical workup of patients has been reported elsewhere [14] . Renal function was quantified by the estimated glomerular filtration rate (eGFR) based on the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation [15] and the albumin:creatinine ratio (ACR) from spot urine. Albuminuria was defined as an ACR >30 mg albumin/g creatinine. Cardiac assessment included echocardiography and electrocardiography. Left ventricular hypertrophy (LVH) was defined as a septal diameter >12 mm. Neurological assessment included a clinical interview focusing on a history of stroke or TIA and an appropriate magnetic resonance imaging. Renal end points were defined as a decrease from CKD stage 1 or 2 to CKD stage !3, dialysis, or renal transplantation. Cardiac end points included the presence of arrhythmia and/or atrial fibrillation, implantation of a cardioverter or pacemaker device or myocardial infarction. Disease severity was also assessed using the Disease Severity Scoring System (DS3; total assessment score: maximum of 80) [16] . FDtypical signs and symptoms as an additional basis for discrimination between classical and late-onset clinical phenotype have been defined as the presence of cornea verticillata, angiokeratoma, diarrhoea (defined as !1 day/month with three loose bowels or >250 g of stool weight/day), hypohidrosis or FDrelated pain at ERT-naïve baseline. Additionally, the presence of CKD, LVH and TIA/stroke at ERT-naïve baseline has been assessed.
GLA sequencing and measurement of GLA activity, plasma lyso-Gb3 and ERT inhibition GLA sequencing for genotyping was performed for all seven coding exons, including the adjacent intron-exon boundaries as described elsewhere [17] . A detailed overview of all detected coding mutations is provided in Supplementary data, Table S1 . Nonsense mutations have been defined as nucleotide exchanges/insertions/deletions resulting in stop codons, frame shifts, large deletions or splice site mutations.
GLA activities were determined using 4-methylumbelliferyla-D-galactopyranoside (Santa Cruz Biotechnology, Heidelberg, Germany) as previously described [18] . N-acetylgalactosamine (Santa Cruz Biotechnology) was used as a specific inhibitor of endogenous a-galactosidase B activity [19] . GLA enzyme activity was determined as nanomoles (nmol) of substrate hydrolysed per hour per milligram of protein or as micromoles per liter per hour. For comparison of GLA units, values were expressed as a percentage of the appropriate reference, based on the median values of the normal control (>33 nmol/h/mg protein or >2.5 mmol/L/h). For plasma lyso-Gb3, lyso-ceramide was used as a reference (Matreya, Pleasant Gap, PA, USA) and D5-fluticasone propionate (EJY Tech, Rockville, MD, USA) was used as an internal standard. Plasma lyso-Gb3 measurement and GLA sequencing as well as GLA activity measurements were performed at the University of Rostock, Germany. Measurement of serum-mediated ERT inhibition in females and males was performed as recently reported [20] . Patients with a mean ERT inhibition of agalsidase-alfa and agalsidasebeta >50% were designated as inhibition-positive according to recent literature [20, 21] .
Statistical analysis
Continuous variables are expressed as mean with standard deviation (SD) or as median (range) if values were unequally distributed. Categorical data are expressed as numbers and frequencies in per cent. Differences between groups were analysed with unpaired Student's t or Mann-Whitney U test for continuous data and Fishers' exact test for categorical data. Differences between the baseline and the end of observation within one group were analysed with paired Student's t-test. Cox proportional hazard models were used to determine the influence of an end point before ERT initiation on the hazard rate for additional end points during the study according to Krall et al. [22] and adjusted for age and sex. Multivariate regression analysis to calculate adjusted eGFR at baseline was also corrected for age and sex. The Kaplan-Meier method was used for survival plots. Linear regression was used to calculate individual yearly eGFR slopes. All results are reported with their respective 95% confidence intervals (CIs). Statistical significance was considered as a two-sided P-value <0.05. SAS version 9.3 (SAS Institute, Cary, NC, USA) and GraphPad Prism version 5.0 software (GraphPad Software, La Jolla, CA, USA) were used for all statistical analyses.
R E S U L T S
In this retrospective longitudinal study, a total of 54 (28 females) genetically confirmed adult patients (mean age 44.5 6 14.7 years) with a clinical classical or late-onset phenotype of FD from centres in Muenster and Cologne were analysed to assess the frequencies of renal, cardiac and neurologic end points during long-term ERT treatment with a mean ERT (Table 1 and Figure 1) . Table 1 provides a comprehensive overview of the baseline characteristics of the study group. We detected 12 renal, 10 cardiac and 9 neurologic end points in 22 patients before ERT was initiated ( Table 1 ). The mean eGFR according to the CKD-EPI equation was 87.1 6 31.5 mL/min/1.73 m 2 , while 27 (54.0%) of the ERTnaïve patients presented with albuminuria and 35 (64.8%) presented with LVH at baseline. The mean interventricular septal end diastole (interventricular septum thickness in diastole (IVSd)) at baseline was 13.4 6 4.6 mm and was comparable between female and male patients (P ¼ 0.3319; Table 1 ). Although females were significantly older than males (P < 0.001), tended to have more nonsense mutations (P ¼ 0.0641) and had higher residual GLA activity (P < 0.001), no sexspecific differences were detected regarding clinical parameters (Table 1) . Thirty-three patients switched from agalsidase-beta to agalsidase-alfa, or vice versa. The mean treatment duration with agalsidase-beta in these patients was 36 6 22 months before dosereduction or switch, indicating a relatively long and clinically relevant treatment period (Table 1 ). There were no significant differences between female and male patients (P ¼ 0.2303). Serum-mediated ERT inhibition was documented in males only (n ¼ 6; P < 0.05). At baseline, ACR values did not differ significantly between females and males, although males tended to present with higher values (P ¼ 0.0675; Table 1 ). During ERT treatment, 11 new renal, 15 new cardiac and 8 new neurologic end points were diagnosed in 27 patients (Table 2) . In detail, eGFR decline resulted in a down-classification from CKD 1 or 2 to CKD 3 or 4 in five patients and from CKD 1-4 to CKD 5 in five patients (Table 2) . One patient received renal transplantation while on ERT (Table 2) . New cardiac end points included seven new cases of arrhythmia/atrial fibrillation, two ICD/pacemaker implantations and six myocardial infarctions. New neurologic end points included eight strokes/TIAs (Table 2) . During ERT treatment, 30 (58.8%) patients received renin-angiotensin-aldosterone system (RAAS) blockers and 16 (31.4%) patients were treated with diuretics (Table 2) . Females received diuretics more often than males (P < 0.05; Table 2 ). During observation, two females died at the ages of 74 and 66 years due to stroke with subsequent sepsis and cardiac decompensation with infection-triggered chronic obstructive lung disease, respectively. The 74-year-old female patient died after 71 months of treatment. At ERT-naïve baseline she suffered from LVH and renal impairment with an eGFR of 55 mL/min/1.73 m 2 and microalbuminuria (CKD G3A2). The 66-year-old female patient died after 70 months of treatment. She also suffered from LVH at baseline, but her renal function was normal with an eGFR of 96 mL/min/1.73 m 2 and no albuminuria. A comparison of patients on ERT with (n ¼ 27) and without end points (n ¼ 27) revealed that sex distribution, age at baseline and ERT duration did not significantly differ between the groups (Table 3) . Patients suffering from a new end point on ERT presented with significantly more end points before ERT initiation (P ¼ 0.01), resulting in a higher total DS3 score at baseline (P ¼ 0.02; Table 3 ). Even if both groups demonstrated a significant increase in DS3 scores during the observation, mean DS3 slopes were significantly steeper in patients on ERT with additional end points (P ¼ 0.01). To confirm an increased risk for an additional end point for patients who had already suffered from an end point before ERT initiation, a stepwise Cox regression analysis was performed. The time at risk covered the period from the patient's ERT initiation until end point occurrence or the end of observation (censoring). The risk to develop a new end point on ERT was significantly increased [hazard ratio (HR) 3.83 (95% CI 1.61-9.08); P ¼ 0.01; corrected Table S2 ). Males with end points on ERT presented more often with LVH at baseline than those without end points on ERT (P ¼ 0.003). This association was not observed in females ( Table 3 ]. Of note, independent of sex, prescription of RAAS blockers was significantly higher in patients with end points on ERT (P < 0.001; Table 3 ). In patients without end points on ERT, the prescription of RAAS blockers ($35%) was low even if $50% suffered from LVH or albuminuria (Table 3) . Interestingly, patients without end points on ERT presented with a significant increase of ACR over time, which was not observed in patients with endpoints (Supplementary data, Figure S1 ). Patients suffering from an end point on ERT presented with a significantly lower eGFR at baseline compared with those without end points (P < 0.001; Table 3 and Figure 2) . A multivariate regression analysis with adjustment for age and sex confirmed this observation and revealed a difference of 24.0 6 6.9 mL/min/1.73 m 2 between both groups at baseline (P < 0.001; Table 3 ), identifying an adjusted filtration rate of 75.0 mL/min/1.73 m 2 /year as a potential predictor to develop end points on ERT. Further analyses applying this identified threshold revealed the following: male and female patients showed significant yearly eGFR declines of Values are given as mean 6 SD or n (%) unless otherwise noted. CKD, chronic kidney disease; DS3, disease severity scoring system; eGFR, estimated glomerular filtration rate (calculated using the CKD-EPI formula according to Levey et al. [15] ); ERT, enzyme replacement therapy; LVH, left ventricular hypertrophy; RAAS, renin-angiotensin-aldosterone system. Figure 3A] , with a median end point-free survival of 62 versus 94 months. A Kaplan-Meier analysis of only cardiovascular end point incidence after ERT initiation demonstrated that the end point-free survival was also severely decreased in patients with an eGFR 75 mL/min/1.73 m 2 at baseline [HR 3. 59 (95% CI 1.15-11.18); P ¼ 0.03; Figure 3B ].
Subsequently we analysed the impact of LVH in patients with an eGFR >75 mL/min/1.73 m 2 at baseline on the development of end points during ERT. The presence of LVH was associated with a decreased end point-free overall survival [HR 6.90 (95% CI 2.04-23.27); P ¼ 0.002; Figure 4 )] but also with an increased age at baseline (P < 0.05).
D I S C U S S I O N
The aim of this study was to analyse the incidence of clinical end points in patients with FD on long-term ERT treatment and to identify differences between those patients.
Our main findings were (i) $40% of patients were diagnosed with clinical end points before ERT initiation, (ii) $50% of patients on ERT developed new clinical end points, (iii) the risk of developing an end point on ERT was increased 3.8-fold in patients who were initially diagnosed with an end point before ERT, (iv) an eGFR 75 mL/min/1.73 m 2 in ERT-naïve patients at baseline predicted an increased risk for end points on ERT and (v) the risk of developing an end point was independent of sex.
Forty per cent of our adult FD patients developed a clinically relevant renal, cardiac and/or neurologic end point prior to ERT, which often led to an FD diagnosis and ERT initiation. Fifty per cent of our patients on ERT for a mean duration of $7 years developed a clinically relevant end point, which is three times the frequency recently reported for clinical events in patients on treatment with agalsidase-beta [10] but comparable to the reported frequency of 50% in patients on agalsidase-alfa reaching ESRD after 10 years of treatment [12] . These different findings might be explained by age (plus $15 years in our group) and renal function at baseline. In our study group, patients were more severely affected, in that the mean eGFR was >30 mL/min/1.73 m 2 lower compared to the cohort reported by Germain et al. [10] . The group analysed by Schiffmann et al. [12] showed ages comparable to our cohort but demonstrated more rapid loss of renal function over time.
Furthermore, our study assessed a combined panel of renal, cardiac and neurologic end points. In patients diagnosed with an end point before ERT initiation, we observed disease progression in that the risk for further clinically relevant end points was increased nearly 4-fold. This disease progression was also well reflected by increasing total DS3 scores. Our observations seem to be in line with previous reports, suggesting the greatest benefits of ERT when it is started at an early stage of disease, i.e. before the onset of fibrosis or other irreversible tissue damage [23] [24] [25] .
In our study, an eGFR 75 mL/min/1.73 m 2 was a strong predictor for a significantly reduced event-free survival. This finding may suggest ongoing disease progression in patients with even moderate kidney impairment despite ERT. As demonstrated by Talbot et al. [13] , the risk of suffering from cardiac events in FD patients with ESRD was significantly increased compared with patients with CKD stages 1-4 [13] . Our results clearly demonstrate that moderately decreased renal function predicts cardiac outcome. In case of severe renal impairment before ERT initiation, individualized treatment (increased frequency of infusions) according to Schiffmann et al. [12] might be an option to slow additional decline in renal function. Furthermore, it has been demonstrated that podocytes are only cleared from the Gb3 load by cumulative agalsidase doses [8, 26] .
As LVH is a typical cardiac manifestation in FD patients and has been associated with disease progression [27] and clinical outcome [27, 28] , we additionally analysed the impact of LVH at baseline in ERT-naïve patients with mild renal impairment (eGFR >75 mL/min/1.73 m 2 ). As expected, patients with LVH at baseline presented with a greater risk of developing any clinically relevant end point. However, affected patients were also significantly older, suggesting that age at ERT initiation is an important determinant for clinical outcome. Of note, the mean age in males and females suffering from LVH at baseline was comparable to those reported by Kampmann et al. [28] . Interestingly, we observed no significant associations between the change of IVSd and the frequencies of end points over time. Our data stress the importance of mildly impaired renal function and the presence of LVH for disease progression/clinical outcome on ERT.
Both sexes demonstrated a significant loss of eGFR over time, although the loss of renal function was twice as high in males as in females ($2.4 versus $1.2 mL/min/1.72 m 2 /year), which is in line with previous reports [10, 29] . In this respect, Warnock et al. [30] reported the safety and efficacy of antiproteinuric therapy RAAS blockers in a study of classical Fabry patients on ERT. Of note, independent of sex, 84% of our patients with end points on ERT received renoprotective RAAS blockers, which is consistent with the frequencies of LVH and albuminuria, but only 35% of patients without end points on ERT received RAAS blockers, which is not fully consistent with the observed frequencies of LVH as well as albuminuria in these patients. This inconsistent renoprotective treatment might explain why these patients demonstrated a significant increase of ACR on ERT over time, necessitating a re-evaluation of these patients.
A high prevalence of uncontrolled blood pressure in patients with FD and worsening CKD has been reported within the Fabry Outcome Survey Registry [31] as well as the Fabry Registry [32] . According to current European Society of Hypertension-European Society of Cardiology guidelines [33] for patients at risk, as well as clinical experience, we propose a target blood pressure of <125/75 mmHg in FD patients with [34] .
Recently, Ortiz et al. [35] reported outcome data from the Fabry Registry from the very beginning of the availability of agalsidase-beta in 2001 until the shortage in 2009, detecting a peak of end points within the first 6 months, which was not observed in our study. The reason for this discrepancy is unclear and studies are not comparable since we included patients on agalsidase-alfa and agalsidase-beta and focused on the very same 54 patients from our FD centres while Ortiz et al. [35] analysed a patient cohort that decreased from 1044 to 356 patients over the observational period. Ortiz et al. [35] stated that within 5 years of observation they detected 177 end points. Since their mean observation length was only 2.8 years, the resulting 'general' frequency of 17% should therefore be interpreted with caution. In our study we detected 27 new end points within the very same patients during a mean follow-up of 5.9 years. In addition, both studies differed in inclusion criteria, event definitions and disease burden, in that the cohort of Ortiz et al. [35] showed a more severe disease progression before ERT initiation, especially in patients >40 years of age.
With respect to our findings, we conclude that in addition to age, even moderately impaired renal function determines FD progression on ERT. In patients with FD, renal protection is warranted to prevent deleterious manifestations. Hence, early ERT initiation and additional renoprotective medication such as RAAS blockers according to current guidelines [36] should be more consistently implemented.
Limitations
Due to missing samples at baseline, no longitudinal analyses of lyso-Gb3 levels could be performed. The absence of renal biopsies to analyse potential intracellular Gb3 inclusions after ERT treatment might be a limitation. Due to the small number of deceased patients (n ¼ 2), no calculations for survival could be performed, necessitating a larger patient cohort or a longer observation period.
S U P P L E M E N T A R Y D A T A
Supplementary data are available online at http://ndt.oxfordjour nals.org.
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